Proteinúria na fibrose cística: possível correlação entre genótipo e fenótipo renal by Cemlyn-Jones, J & Gamboa, F
J Bras Pneumol. 2009;35(7):669-675
Proteinuria in cystic fibrosis: a possible correlation  
between genotype and renal phenotype*, **
Proteinúria na fibrose cística: possível  
correlação entre genótipo e fenótipo renal
Jessica Cemlyn-Jones, Fernanda Gamboa
Abstract
Objective: To assess proteinuria in patients with cystic fibrosis (CF), and to correlate proteinuria with genotype, 
CF-related diabetes and disease severity. Methods: A prospective study was carried out over a six-month period 
and involving 22 CF patients. After the collection and analysis of 24-h urine samples, the patients were divided 
into two subgroups: protein excretion < 150 mg/day (low-proteinuria); and protein excretion ≥ 150 mg/day (high-
proteinuria). Patient charts were reviewed to obtain data on genotype and CF-related diabetes. Disease severity was 
assessed based on acute exacerbations in the last six months and FEV1 measured during the study period. To assess 
the correlation between genotype and proteinuria, the two main mutations (ΔF508 and R334W) were evaluated. 
Due to the existence of genotype ΔF508/R334W, two categories were created to enable statistical analysis, ΔF508 
being evaluated in category 1 and R334W being evaluated in category 2. Results: The ΔF508 mutation tended 
to be associated with normal protein excretion: 100% of the low-proteinuria subgroup patients were considered 
ΔF508 in category 1, compared with 86.7% in category 2. Protein excretion tended to be higher in patients with 
the R334W mutation: 60.0% of the high-proteinuria subgroup patients were considered R334W in category 1, 
compared with 80.0% in category 2 (p = 0.009 and p = 0.014, respectively). No significant association was found 
for any of the other variables. Conclusions: The results suggest that genotype is associated with renal phenotype, 
depending on the mechanism by which the genotype alters the function of the cystic fibrosis transmembrane 
conductance regulator gene. 
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Resumo
Objetivo: Avaliar a proteinúria em pacientes com fibrose cística (FC) e correlacioná-la com o genótipo, com a 
diabetes relacionada à FC e com a gravidade da doença. Métodos: Estudo prospectivo realizado num período de 
seis meses com 22 pacientes com FC. Efetuada proteinúria de 24 h com a divisão dos pacientes em dois subgrupos: 
proteinúria < 150 mg/dia (proteinúria-baixa); e proteinúria ≥ 150 mg/dia (proteinúria-alta). Revisamos os prontuá-
rios clínicos para a coleta de informações sobre o genótipo e a presença de diabetes relacionada à FC. A gravidade 
da doença foi avaliada pelas exacerbações agudas no último semestre e pelo VEF1 durante o período de estudo. 
Para avaliar a correlação entre genótipo e proteinúria, consideraram-se as duas principais mutações, ΔF508 e 
R334W. Dada a existência do genótipo ΔF508/R334W, foram criadas duas categorias para se proceder à avaliação 
estatística, sendo esse genótipo considerado ΔF508 na categoria 1 e R334W na categoria 2. Resultados: A mutação 
ΔF508 se associou com valores normais de proteinúria: 100% dos pacientes do subgrupo proteinúria-baixa foram 
considerados ΔF508 na categoria 1, comparados a 86,7% na categoria 2. Em pacientes com a mutação R334W, os 
valores de proteinuria foram mais elevados: 60,0% dos pacientes do subgrupo proteinúria-alta foram considerados 
R334W na categoria 1, comparados a 80,0% na categoria 2 (p = 0,009 e p = 0,014, respectivamente). Para as 
outras variáveis, não houve associação significativa. Conclusões: Os resultados sugerem que há uma associação 
entre o genótipo e o fenótipo renal, dependendo do mecanismo pelo qual o genótipo altera a função do gene 
regulador de condutância transmembrana da fibrose cística. 
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The CFTR gene is abundantly expressed in 
all nephron segments. However, there seems 
to be no clear renal phenotype and no major 
primary renal dysfunction. Renal abnormalities 
in CF tend to be due either to secondary causes 
or to associated conditions. These include 
exposure to aminoglycosides and other neph-
rotoxic antibiotics or drugs, as well as immune 
complex-mediated injury in the presence of 
chronic bacterial infection, diabetes mellitus, 
liver disease, cor pulmonale, malabsorption or 
steatorrhea. Hypoxemia in severe lung disease 
can increase the nephrotoxic potentials of these 
risk factors.(7) 
In recent years, reports of renal disease in 
CF patients have been increasing, although 
there is still a shortage of clinical reporting. The 
following alterations have all been described 
in CF patients: glomerulosclerosis; immune 
complex deposition; IgA nephropathy; mesangial 
proliferation; nephrocalcinosis; microscopic 
hematuria; tubular injury; diabetic nephropathy; 
fibrillary glomerulonephritis; and amyloidosis. 
Aberrant CFTR expression might explain the 
subtle abnormalities in renal concentrating 
and diluting ability described in CF, as well as 
the increased incidence of nephrocalcinosis.(8) 
Recent studies have suggested that the loss of 
CFTR gene function interferes with the handling 
of low-molecular-weight proteins through 
impairment of receptor mediator endocytosis in 
proximal tubule cells, thereby leading to selective 
proteinuria.(9) However, CFTR gene expression 
and processing in the kidney is not fully under-
stood, and no predominant renal phenotype has 
yet been documented in CF patients. 
In one study, it was reported that 5 of the 
23 patients evaluated in an autopsy series had 
Introduction
Cystic fibrosis (CF) is the most common 
fatal autosomal recessive disease among White 
people and is caused by mutations in a single 
gene known as the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, a complex 
chloride channel found in all exocrine tissues.
More than 1,300 CFTR gene mutations have 
been reported to the Cystic Fibrosis Genetic 
Analysis Consortium.(1) These mutations fall into 
five classes based on their effect on protein 
structure or function(1); class I mutations lead 
to the disruption of the CFTR protein synthesis; 
class II mutations are associated with defective 
protein processing; class III mutations lead to 
the production of proteins that reach the plasma 
membrane but with defective regulation, which 
prevents them from being activated; class IV 
mutations are associated with altered conduct-
ance such that the rate of chloride transport 
is reduced; and class V mutations lead to the 
production of normal proteins but at reduced 
levels. Class I, II and III mutations are considered 
severe.
The ΔF508 mutation is a class II mutation 
and accounts for approximately 70% of chro-
mosomes in CF patients. The majority of the 
other CFTR mutations are quite rare.(2)
The clinical spectrum of CF is highly variable, 
ranging from severe disease with pancreatic 
insufficiency and early lung involvement to a 
much milder form.(3) There appears to be a rela-
tively strong correlation between the CFTR gene 
mutation and the phenotype in the pancreas and 
gastrointestinal tract, although this  correlation is 
much weaker in the lung. Little is known about 
this correlation in the kidney.(4) Patients with 
pancreatic sufficiency have at least one mild 
allele (a class IV mutation, partial missplicing 
of a class I mutation or a mutation affecting 
protein stability), whereas patients with pancre-
atic insufficiency are homozygous or compound 
heterozygous for two severe (class I, II or III) 
mutations. The pulmonary component of CF 
is highly variable, even among siblings with 
identical mutations. Recent reports have demon-
strated a correlation between certain mutations 
and the severity of lung disease.(5) However, it 
still seems that CFTR mutations have a more 
variable impact on the pulmonary phenotype, in 
which modifier genes and environmental effects 
also contribute to disease severity.(6)
Table 1 - Demographic and clinical characteristics of 
the cystic fibrosis patients evaluated.
Characteristic Study group 
(n = 22)
Age in years, mean ± SD (range) 25 ± 6 (14-35)
Gender
Female, n (%) 15 (68)
Male, n (%) 7 (32)
Chronic bacterial colonization, n (%) 22 (100)
Cystic fibrosis-related diabetes, n (%) 5 (23)
Acute exacerbation in last 6 months, 
n (%)
6 (27)
FEV1 ≤ 50%, n (%) 8 (36)
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biopsies are rarely performed, which seems to 
suggest that isolated proteinuria is not sufficient 
to prompt histological confirmation.
The aim of this study was to assess protein 
excretion in a population of CF patients, as 
well as to determine whether protein excretion 
correlates with genotype, cystic fibrosis-related 
diabetes (CFRD) and disease severity.
Since the exact prevalence of proteinuria 
is not known in the general population, 24-h 
protein excretion was also evaluated in a group 
of healthy controls.
Methods
This was a prospective study of adult 
CF patients treated in the Department of 
Pulmonology and Allergology of the Hospitals of 
the University of Coimbra, located in the city of 
Coimbra, Portugal, over a period of six months. 
Of the 24 CF patients treated during that period, 
2 were also lung transplant patients and were 
excluded, since the pharmacological treatment 
a history of unexplained proteinuria in routine 
analysis, and that the majority of these patients 
presented renal pathology at autopsy.(10) 
In CF patients, urinalysis often reveals 
mild proteinuria.(11) However, some of the case 
studies in this field have reported relevant issues, 
including the fact that CF patients with renal 
disease can present significant proteinuria, 
although kidney function (blood urea nitrogen 
and creatinine) can be normal.(12) Proteinuria 
progressing to nephrotic syndrome has an 
extremely poor prognosis.(13,14)
In healthy persons, mean urinary protein 
excretion is 60-80 mg, with an upper limit of 
150 mg/day.(7) Current evidence indicates that 
proteinuria is an early marker of an increased risk 
of progressive kidney disease, poor cardiovascular 
outcome and death. Among the various predic-
tors of progression of chronic kidney disease to 
end stage renal disease, proteinuria is the most 
important.(15,16) In CF patients, urinalysis can be 
helpful, and proteinuria should raise the suspi-
cion of CF-related renal disease. However, renal 
Table 2 - Clinical variables, by individual genotype, for the 22 cystic fibrosis patients evaluated.
Patient genotype Variable
Protein excretion CFRD Acute exacerbations 
in the last 6 months
FEV1
(mg/24 h) (%)
A516E/A516E 156 yes yes 20.7
ΔF508/ΔF508 92 no yes 22
ΔF508/ΔF508 77.3 no no 111
ΔF508/ΔF508 62.7 no no 79.0
ΔF508/ΔF508 73.5 no no 73.7
ΔF508/ΔF508 84 yes yes 39.2
ΔF508/ΔF508 128.8 yes no 71.1
ΔF508/ΔF508 132 no no 58.4
ΔF508/ΔF508 160 no no 87.9
ΔF508/ΔF508 76.5 yes no 63.0
ΔF508/ΔF508 80 no no 48.8
ΔF508/P205S 78 no no 81
ΔF508/P205S 143.4 no no 54.0
ΔF508/P205S 88.8 no no 112.7
ΔF508/R1066C 70 no yes 42.3
ΔF508/R334W 73.9 no no 40
ΔF508/R334W 184.5 no no 79.6
ΔF508/R334W 133.2 no no 98.6
ΔF508del/NIM 134.6 yes no 98
R334W/R334W 179 no no 63.0
R334W/R334W 156 no yes 33.8
R334W/R334W 949 no yes 50.4
CFRD: cystic fibrosis-related diabetes.
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various qualitative variables. Mean and standard 
deviation were calculated for quantitative vari-
ables. Differences between subgroups were 
analyzed using Pearson’s chi-square test or 
Fisher’s exact test for qualitative variables and 
the Mann-Whitney test (for two independent 
samples) for quantitative variables. 
To assess differences between the subgroups, 
considering genotype categories, Pearson’s 
chi-square test or Fisher’s exact test was used. 
Values of p < 0.05 were considered statistically 
significant.
for lung transplant can influence renal func-
tion. Therefore, the final study sample consisted 
of 22 CF patients. We also recruited a group of 
22 healthy adult controls composed of doctors, 
nurses and family members of Department 
staff.
After the objective of the study had been 
explained to all of the participants, 24-h urine 
samples, each including an overnight sample,(17) 
were collected. Samples were not collected when 
patients had infectious exacerbations or had 
recently received intravenous aminoglycosides.
Since mild proteinuria is frequently found in 
CF patients, the study group was divided into 
two subgroups, based on a protein excretion 
cut-off value of 150 mg/24 h: protein excre-
tion < 150 mg/day (low-proteinuria subgroup); 
and protein excretion ≥ 150 mg/day (high-pro-
teinuria subgroup).
In all CF patients, genotyping is carried out 
at initial diagnosis, and an oral glucose tolerance 
test, including fasting glycemia and measure-
ment of glycemia after ingestion of glucose 
solution (maximum, 75 g), is performed annu-
ally to screen for CFRD. Patient records were 
reviewed in order to obtain these data. 
Patients participating in the present study 
were submitted to spirometry, and we consid-
ered FEV1 < 50% a marker of impaired lung 
function.(18,19) Having presented infectious exac-
erbations in the last six months was considered 
an indicator of disease severity.(20)
To assess the correlation between genotype 
and protein excretion, the two main CFTR gene 
mutations (ΔF508 and R334W) were evalu-
ated. Due to the existence of the ΔF508/R334W 
genotype, two categories were created to enable 
accurate statistical analysis, ΔF508 being evalu-
ated in category 1 and R334W being evaluated 
in category 2.
Cases in which the patient carried neither the 
ΔF508 nor the R334W genotype were excluded, 
as were those in which the patient carried an 
unidentified mutation. Consequently, the final 
number of genotypes evaluated in each category 
was 20.
Statistical analysis
Data were analyzed using the program 
Statistical Package for the Social Sciences, 
version 15.0 (SPSS Inc, Chicago, IL, USA). 
Frequency distribution was obtained for the 
Table 3 - Distribution according to 24-h urinary 






















Low-proteinuria: 24-h protein excretion < 150 mg/day; and 
High-proteinuria: 24-h protein excretion ≥ 150 mg/day.
Table 4 - Genotype frequency by category, stratified 
according to ΔF508 and R334W mutations.
Genotype category Valid genotype Frequency (n)
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to renal biopsy. Histological analysis of the 
biopsy sample revealed mesangioproliferative 
glomerulonephritis with IgM deposition.
There were 16 patients in the low-proteinuria 
subgroup and 6 patients in the high-proteinuria 
subgroup. The frequency of genotypes in each 
subgroup is shown in Table 3. 
All patients who were R334W/R334W 
homozygotes were in the high-proteinuria 
subgroup. In the low-proteinuria subgroup, 
9 patients were ΔF508/ΔF508 homozygotes 
(56.3% within the subgroup). There was only 
one ΔF508/ΔF508 homozygote in the high-
proteinuria subgroup.
The categorical analysis of the two main 
mutations (ΔF508 and R334W) is shown in 
Table 4. The two cases already mentioned 
(A516E/A516E and F508del/NIM) were not 
included in either category. 
As can be seen in Table 5, the ΔF508 muta-
tion tends to be associated with normal protein 
excretion. In the low-proteinuria subgroup, all 
patients were ΔF508 in the category 1 anal-
ysis, and 86.7% were ΔF508 in the category 2 
analysis. In patients with the R334W mutation, 
protein excretion tended to be higher. In the 
high-proteinuria subgroup, 60% of the patients 
were R334W in the category 1 analysis, compared 
with 80% in the category 2 analysis (p = 0.009 
for category 1 and p = 0.014 for category 2). 
No significant relationship was found between 
Results
Patient demographic data are shown in 
Table 1. The mean age was 25 ± 6 years in the CF 
group and 24 ± 6 years in the control group.
Of the 22 CF patients evaluated, 5 (22%) had 
CFRD. All 22 patients had chronic bacterial colo-
nization, 6 (27%) had experienced one or more 
acute exacerbations requiring management with 
intravenous antibiotics in the last six months, 
and 8 (36%) had an FEV1 < 50%.
The mean urinary protein excretion among 
the CF patients was 150.6 ± 182.6 mg/24 h, 
with a 5% trimmed mean of 114.95 mg/dL 
(95% CI: 69.66-231.54), compared with 89.08 ± 
26.64 mg/24 h, with a 5% trimmed mean of 
87.45 mg/dL (95% CI: 72.77-100.89), among 
the controls. 
A statistically significant difference was 
found between the CF group and the control 
group in terms of mean urinary protein excre-
tion (p < 0.05).
Table 2 shows the clinical variables, by indi-
vidual genotype, for each of the 22 CF patients 
evaluated.
Among the 22 CF group patients, protein 
excretion was ≥ 150 mg/day in 6 (27.3%), 1 of 
whom had significant proteinuria (949 mg/day). 
Another of those 6 also had CFRD. There were 
8 CF group patients (36.4%) with an FEV1 ≤ 50%, 
and protein excretion was ≥ 150 mg/day in 
3 of those patients. The patient who presented 
protein excretion of 949 mg/day was submitted 
Table 5 - Subgroup analysis according to 24-h proteinuria in relation to genotype category, cystic fibrosis-
related diabetes, disease severity and pulmonary function.




(≥ 150 mg/day) 
22 (100) 16 (72.7) 6 (27.3)
Genotype category
Category 1
ΔF508, n (%) 15 (100.0) 2 (40.0) 0.009
R334W, n (%) 0 (0.0) 3 (60.0)
Category 2
ΔF508, n (%) 13 (86.7) 1 (20.0) 0.014
R334W, n (%) 2 (13.3) 4 (80.0)
CFRD, n (%) 5 (23) 4 (25) 1 (16.7) 0.399
Acute exacerbations in  
the last 6 months, n (%) 
6 (27) 3 (18.8) 3 (50) 0.366
FEV1 < 50%, n (%) 8 (36) 5 (31.3) 3 (50) 0.381
CFRD: cystic fibrosis-related diabetes.
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that, although microalbuminuria is a sensitive 
indicator of progression to diabetic nephropathy 
in non-CF diabetes, it is less sensitive for CF 
patients, due to confounding factors.(24) Further 
studies are required in order to clarify whether 
microalbuminuria is a useful tool for predicting 
progression to diabetic nephropathy in subjects 
with CFRD and whether this notion could be 
extrapolated to proteinuria as a screening tool 
for CF-related renal disease.
The overall treatment now given to children 
with CF from the time of diagnosis has notably 
increased their life expectancy.(25) The selec-
tion of candidates for transplant is crucial for 
their long term survival, and there is a growing 
emphasis on prevention of complications in 
organs other than the lung. Increased survival 
has emphasized the importance of liver disease, 
which is now the third leading cause of death 
among adults with CF.(26) Recent reports suggest 
that focused care and adequate screening have 
contributed to maintaining clinical stability in 
adult CF patients with liver abnormalities.(27) 
Few studies have addressed the prevalence and 
natural history of renal disease in adults with 
CF. However, clinical reporting of renal abnor-
malities is increasing, and the determination of 
urinary protein excretion could prove useful in 
identifying CF patients at risk for progressive 
renal injury. 
In the present study, we found a posi-
tive correlation between protein excretion and 
genotype in CF patients. This suggests that renal 
phenotype is associated with CFTR gene muta-
tion, perhaps according to the mechanism by 
which each mutation disrupts CFTR function.
In the routine evaluation of renal function 
in CF patients, special attention is now given 
to R334W genotypes. We recommend that 
24-h urinary protein excretion be  measured 
on an annual basis in all CF patients. Those 
in whom protein excretion is ≥ 150 mg/dL 
should undergo further testing. If serum creati-
nine is > 1.4 mg/dL, abdominal ultrasound 
is indicated, and patients with significant 
proteinuria (> 1 g/day) should be submitted to 
renal biopsy.
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Discussion
The class II mutations ΔF508 and R1066C 
are associated with defective protein processing, 
resulting in CFTR protein synthesis that fails 
to reach the apical membrane.(1) The class IV 
mutations R334W and P205S produce a cyclic 
adenosine monophosphate-responsive channel 
with reduced conductance, thereby reducing 
chloride transport.(21)
In the present study, the patients with the 
ΔF508 mutation presented lower protein excre-
tion than did those with the R334W mutation 
(p < 0.05). Protein excretion was normal in 90% 
of the patients who were homozygous for ΔF508 
and in 100% of those with the ΔF508/P205S 
genotype. In the category 1 analysis, 66.7% of 
the patients with the ΔF508/R334W genotype 
also presented protein excretion < 150 mg/dL. 
Homozygosity for the R334W mutation seems 
to predispose to higher protein excretion (all 
R334W/R334W homozygotes were in the high-
proteinuria subgroup). In fact, the highest 
protein excretion observed (949 mg/day) was in 
one of the R334W/R334W homozygotes.
All of the CF group patients had chronic 
bacterial colonization. Lung injury due to post-
colonization tissue inflammation leads to the 
increased cytokine levels that precede lung 
function impairment. Elevated cytokine levels 
stimulate bone resorption, which might be a 
contributing factor to the association between 
decreased FEV1 and low bone mineral density 
reported in the CF population.(22) Likewise, 
immune complex-mediated injury in the pres-
ence of chronic bacterial infection can impair 
renal function.(23) However, in the present study, 
disease severity, based on FEV1 values and infec-
tious exacerbations in the last six months, did 
not correlate with proteinuria (p = 0.366). This 
might be partly explained by the fact that, even 
in the patients with severe disease, there was no 
significant exposure to aminoglycosides. One 
patient had received intravenous tobramycin due 
to an acute episode, after which protein excre-
tion returned to normal (70 mg/dL). 
No association was found between high 
protein excretion and CFRD (p = 0.399), protein 
excretion being ≥ 150 mg/dL in only one case 
of CFRD. This might be explained by the fact 
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